Constipation in CKD

Keiichi Sumida, Kunihiro Yamagata, Csaba P Kovesdy, Keiichi Sumida, Kunihiro Yamagata, Csaba P Kovesdy

Abstract

Constipation is one of the most common gastrointestinal disorders among patients with chronic kidney disease (CKD) partly because of their sedentary lifestyle, low fiber and fluid intake, concomitant medications (e.g., phosphate binders), and multiple comorbidities (e.g., diabetes). Although constipation is usually perceived as a benign, often self-limited condition, recent evidence has challenged this most common perception of constipation. The chronic symptoms of constipation negatively affect patients' quality of life and impose a considerable social and economic burden. Furthermore, recent epidemiological studies have revealed that constipation is independently associated with adverse clinical outcomes, such as end-stage renal disease (ESRD), cardiovascular (CV) disease, and mortality, potentially mediated by the alteration of gut microbiota and the increased production of fecal metabolites. Given the importance of the gut in the disposal of uremic toxins and in acid-base and mineral homeostasis with declining kidney function, the presence of constipation in CKD may limit or even preclude these ancillary gastrointestinal roles, potentially contributing to excess morbidity and mortality. With the advent of new drug classes for constipation, some of which showing unique renoprotective properties, the adequate management of constipation in CKD may provide additional therapeutic benefits beyond its conventional defecation control. Nevertheless, the problem of constipation in CKD has long been underrecognized and its management strategies have scarcely been documented. This review outlines the current understanding of the diagnosis, prevalence, etiology, outcome, and treatment of constipation in CKD, and aims to discuss its novel clinical and therapeutic implications.

Keywords: cardiovascular disease; chronic kidney disease; constipation; end-stage renal disease; gut microbiota; laxative.

© 2019 International Society of Nephrology. Published by Elsevier Inc.

Figures

Figure 1
Figure 1
Visual illustration of Bristol Stool Form Scale. Reprinted with permission from Chumpitazi BP, Self MM, Czyzewski DI, et al. Bristol Stool Form Scale reliability and agreement decreases when determining Rome III stool form designations. Neurogastroenterol Motil. 2016;28:443–448.
Figure 2
Figure 2
Medical conditions associated with constipation in chronic kidney disease. CCB, calcium channel blocker; NSAID, nonsteroidal anti-inflammatory drug.
Figure 3
Figure 3
Schematic representation of potential mechanisms underlying the association between constipation and adverse outcomes in chronic kidney disease (CKD). CVD, cardiovascular disease; TMAO, trimethylamine-N-oxide.
Figure 4
Figure 4
Cumulative probability of (a) incident chronic kidney disease (CKD) and (b) incident end-stage renal disease (ESRD) according to constipation status. Reprinted with permission of the American Society of Nephrology from Constipation and incident CKD, Sumida K, Molnar MZ, Potukuchi PK, et al. J Am Soc Nephrol., volume 28, issue 4, Copyright © 2017; permission conveyed through Copyright Clearance Center, Inc.

References

    1. Bharucha A.E., Pemberton J.H., Locke G.R., 3rd American Gastroenterological Association technical review on constipation. Gastroenterology. 2013;144:218–238.
    1. Strid H., Simren M., Johansson A.C. The prevalence of gastrointestinal symptoms in patients with chronic renal failure is increased and associated with impaired psychological general well-being. Nephrol Dial Transplant. 2002;17:1434–1439.
    1. Yasuda G., Shibata K., Takizawa T. Prevalence of constipation in continuous ambulatory peritoneal dialysis patients and comparison with hemodialysis patients. Am J Kidney Dis. 2002;39:1292–1299.
    1. Cano A.E., Neil A.K., Kang J.Y. Gastrointestinal symptoms in patients with end-stage renal disease undergoing treatment by hemodialysis or peritoneal dialysis. Am J Gastroenterol. 2007;102:1990–1997.
    1. Shirazian S., Radhakrishnan J. Gastrointestinal disorders and renal failure: exploring the connection. Nat Rev Nephrol. 2010;6:480–492.
    1. Wu M.J., Chang C.S., Cheng C.H. Colonic transit time in long-term dialysis patients. Am J Kidney Dis. 2004;44:322–327.
    1. Himmelfarb J. Uremic toxicity, oxidative stress, and hemodialysis as renal replacement therapy. Semin Dial. 2009;22:636–643.
    1. Ramezani A., Massy Z.A., Meijers B. Role of the gut microbiome in uremia: a potential therapeutic target. Am J Kidney Dis. 2016;67:483–498.
    1. Attaluri A., Jackson M., Valestin J., Rao S.S. Methanogenic flora is associated with altered colonic transit but not stool characteristics in constipation without IBS. Am J Gastroenterol. 2010;105:1407–1411.
    1. Quigley E.M. The enteric microbiota in the pathogenesis and management of constipation. Best Pract Res Clin Gastroenterol. 2011;25:119–126.
    1. Dennison C., Prasad M., Lloyd A. The health-related quality of life and economic burden of constipation. Pharmacoeconomics. 2005;23:461–476.
    1. Sun S.X., Dibonaventura M., Purayidathil F.W. Impact of chronic constipation on health-related quality of life, work productivity, and healthcare resource use: an analysis of the National Health and Wellness Survey. Dig Dis Sci. 2011;56:2688–2695.
    1. Guerin A., Carson R.T., Lewis B. The economic burden of treatment failure amongst patients with irritable bowel syndrome with constipation or chronic constipation: a retrospective analysis of a Medicaid population. J Med Econ. 2014;17:577–586.
    1. Sumida K., Molnar M.Z., Potukuchi P.K. Constipation and incident CKD. J Am Soc Nephrol. 2017;28:1248–1258.
    1. Salmoirago-Blotcher E., Crawford S., Jackson E. Constipation and risk of cardiovascular disease among postmenopausal women. Am J Med. 2011;124:714–723.
    1. Kubota Y., Iso H., Tamakoshi A. Bowel movement frequency, laxative use, and mortality from coronary heart disease and stroke among japanese men and women: The Japan Collaborative Cohort (JACC) Study. J Epidemiol. 2016;26:242–248.
    1. Honkura K., Tomata Y., Sugiyama K. Defecation frequency and cardiovascular disease mortality in Japan: the Ohsaki cohort study. Atherosclerosis. 2016;246:251–256.
    1. Sumida K., Molnar M.Z., Potukuchi P.K. Constipation and risk of death and cardiovascular events. Atherosclerosis. 2019;281:114–120.
    1. Mishima E., Fukuda S., Shima H. Alteration of the intestinal environment by lubiprostone is associated with amelioration of adenine-induced CKD. J Am Soc Nephrol. 2015;26:1787–1794.
    1. Sueyoshi M., Fukunaga M., Mei M. Effects of lactulose on renal function and gut microbiota in adenine-induced chronic kidney disease rats. Clin Exp Nephrol. 2019;23:908–919.
    1. Nanto-Hara F, Kanemitsu Y, Fukuda S, et al. The guanylate cyclase C agonist linaclotide ameliorates the gut-cardio-renal axis in an adenine-induced mouse model of chronic kidney disease [e-pub ahead of print]. Nephrol Dial Transplant. . Accessed December 4, 2019.
    1. Svedlund J., Sjodin I., Dotevall G. GSRS--a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci. 1988;33:129–134.
    1. Agachan F., Chen T., Pfeifer J. A constipation scoring system to simplify evaluation and management of constipated patients. Dis Colon Rectum. 1996;39:681–685.
    1. Lewis S.J., Heaton K.W. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol. 1997;32:920–924.
    1. Riegler G., Esposito I. Bristol scale stool form. A still valid help in medical practice and clinical research. Tech Coloproctol. 2001;5:163–164.
    1. Krogh K., Christensen P., Sabroe S., Laurberg S. Neurogenic bowel dysfunction score. Spinal Cord. 2006;44:625–631.
    1. Basilisco G., Coletta M. Chronic constipation: a critical review. Dig Liver Dis. 2013;45:886–893.
    1. Mearin F., Lacy B.E., Chang L. Bowel disorders. Gastroenterology. 2016;150:1393–1470.
    1. Saad R.J., Rao S.S., Koch K.L. Do stool form and frequency correlate with whole-gut and colonic transit? Results from a multicenter study in constipated individuals and healthy controls. Am J Gastroenterol. 2010;105:403–411.
    1. Chumpitazi B.P., Self M.M., Czyzewski D.I. Bristol Stool Form Scale reliability and agreement decreases when determining Rome III stool form designations. Neurogastroenterol Motil. 2016;28:443–448.
    1. Quigley E.M.M., Horn J., Kissous-Hunt M. Better Understanding and Recognition of the Disconnects, Experiences, and Needs of Patients with Irritable Bowel Syndrome with Constipation (BURDEN IBS-C) study: results of an online questionnaire. Adv Ther. 2018;35:967–980.
    1. Trimingham C., McDonald S., Dansie K. Bowel health in chronic kidney disease: patient perceptions differ from clinical definitions. J Ren Care. 2018;44:65–72.
    1. Mugie S.M., Benninga M.A., Di Lorenzo C. Epidemiology of constipation in children and adults: a systematic review. Best Pract Res Clin Gastroenterol. 2011;25:3–18.
    1. Galvez C., Garrigues V., Ortiz V. Healthcare seeking for constipation: a population-based survey in the Mediterranean area of Spain. Aliment Pharmacol Ther. 2006;24:421–428.
    1. Hammer J., Oesterreicher C., Hammer K. Chronic gastrointestinal symptoms in hemodialysis patients. Wien Klin Wochenschr. 1998;110:287–291.
    1. Bossola M., Luciani G., Rosa F., Tazza L. Appetite and gastrointestinal symptoms in chronic hemodialysis patients. J Ren Nutr. 2011;21:448–454.
    1. Zhang J., Huang C., Li Y. Health-related quality of life in dialysis patients with constipation: a cross-sectional study. Patient Prefer Adherence. 2013;7:589–594.
    1. Chong V.H., Tan J. Prevalence of gastrointestinal and psychosomatic symptoms among Asian patients undergoing regular hemodialysis. Nephrology (Carlton) 2013;18:97–103.
    1. Dong R., Guo Z.Y., Ding J.R. Gastrointestinal symptoms: a comparison between patients undergoing peritoneal dialysis and hemodialysis. World J Gastroenterol. 2014;20:11370–11375.
    1. Ikee R., Toyoyama T., Endo T. Clinical factors associated with constipation in hemodialysis patients. Int Urol Nephrol. 2016;48:1741–1742.
    1. Zuvela J., Trimingham C., Le Leu R. Gastrointestinal symptoms in patients receiving dialysis: a systematic review. Nephrology (Carlton) 2018;23(8):718–727.
    1. Salamon K., Woods J., Paul E., Huggins C. Peritoneal dialysis patients have higher prevalence of gastrointestinal symptoms than hemodialysis patients. J Ren Nutr. 2013;23:114–118.
    1. Ramos C.I., Andrade de Lima A.F., Grilli D.G., Cuppari L. The short-term effects of olive oil and flaxseed oil for the treatment of constipation in hemodialysis patients. J Ren Nutr. 2015;25:50–56.
    1. Wang H.F., Lim P.S., Kao M.D. Use of isomalto-oligosaccharide in the treatment of lipid profiles and constipation in hemodialysis patients. J Ren Nutr. 2001;11:73–79.
    1. Daniels G., Robinson J.R., Walker C. Gastrointestinal symptoms among African Americans undergoing hemodialysis. Nephrol Nurs J. 2015;42:539–548. quiz 549.
    1. Dong R., Guo Z.Y. Gastrointestinal symptoms in patients undergoing peritoneal dialysis: multivariate analysis of correlated factors. World J Gastroenterol. 2010;16:2812–2817.
    1. Mitrovic M., Majster Z. The prevalence, severity and diversity of gastrointestinal symptoms in hemodialysis and peritoneal dialysis patients. Nephrol Dial Transplant. 2015;30:SP706.
    1. Lee A., Lambert K., Byrne P., Lonergan M. Prevalence of constipation in patients with advanced kidney disease. J Ren Care. 2016;42:144–149.
    1. American Gastroenterological Association. Bharucha A.E., Dorn S.D. American Gastroenterological Association medical position statement on constipation. Gastroenterology. 2013;144:211–217.
    1. Tack J., Muller-Lissner S., Stanghellini V. Diagnosis and treatment of chronic constipation--a European perspective. Neurogastroenterol Motil. 2011;23:697–710.
    1. Camilleri M. Peripheral mechanisms in irritable bowel syndrome. N Engl J Med. 2012;367:1626–1635.
    1. Longstreth G.F., Thompson W.G., Chey W.D. Functional bowel disorders. Gastroenterology. 2006;130:1480–1491.
    1. He C.L., Burgart L., Wang L. Decreased interstitial cell of cajal volume in patients with slow-transit constipation. Gastroenterology. 2000;118:14–21.
    1. Tzavella K., Riepl R.L., Klauser A.G. Decreased substance P levels in rectal biopsies from patients with slow transit constipation. Eur J Gastroenterol Hepatol. 1996;8:1207–1211.
    1. Cortesini C., Cianchi F., Infantino A., Lise M. Nitric oxide synthase and VIP distribution in enteric nervous system in idiopathic chronic constipation. Dig Dis Sci. 1995;40:2450–2455.
    1. Rao S.S., Welcher K.D., Leistikow J.S. Obstructive defecation: a failure of rectoanal coordination. Am J Gastroenterol. 1998;93:1042–1050.
    1. Muller-Lissner S.A. Effect of wheat bran on weight of stool and gastrointestinal transit time: a meta analysis. Br Med J (Clin Res Ed) 1988;296:615–617.
    1. Voderholzer W.A., Schatke W., Muhldorfer B.E. Clinical response to dietary fiber treatment of chronic constipation. Am J Gastroenterol. 1997;92:95–98.
    1. Mugie S.M., Di Lorenzo C., Benninga M.A. Constipation in childhood. Nat Rev Gastroenterol Hepatol. 2011;8:502–511.
    1. Haug T.T., Mykletun A., Dahl A.A. Are anxiety and depression related to gastrointestinal symptoms in the general population? Scand J Gastroenterol. 2002;37:294–298.
    1. Lindberg G., Hamid S.S., Malfertheiner P. World Gastroenterology Organisation global guideline: constipation--a global perspective. J Clin Gastroenterol. 2011;45:483–487.
    1. Zoccali C., Tripepi G., Mallamaci F. Predictors of cardiovascular death in ESRD. Semin Nephrol. 2005;25:358–362.
    1. Evenepoel P., Meijers B.K., Bammens B.R., Verbeke K. Uremic toxins originating from colonic microbial metabolism. Kidney Int Suppl. 2009:S12–S19.
    1. Campbell A.J., Busby W.J., Horwath C.C. Factors associated with constipation in a community based sample of people aged 70 years and over. J Epidemiol Community Health. 1993;47:23–26.
    1. Bouchoucha M., Devroede G., Bon C. Difficult defecation in constipated patients and its relationship to colonic disorders. Int J Colorectal Dis. 2016;31:685–691.
    1. Chang J.Y., Locke G.R., Schleck C.D. Risk factors for chronic constipation and a possible role of analgesics. Neurogastroenterol Motil. 2007;19:905–911.
    1. Fosnes G.S., Lydersen S., Farup P.G. Drugs and constipation in elderly in nursing homes: what is the relation? Gastroenterol Res Pract. 2012;2012:290231.
    1. Wein S. Opioid-induced constipation. J Pain Palliat Care Pharmacother. 2012;26:382–384.
    1. Bennett W.E., Jr., Heuckeroth R.O. Hypothyroidism is a rare cause of isolated constipation. J Pediatr Gastroenterol Nutr. 2012;54:285–287.
    1. Ragno A., Pepe J., Badiali D. Chronic constipation in hypercalcemic patients with primary hyperparathyroidism. Eur Rev Med Pharmacol Sci. 2012;16:884–889.
    1. Boobes K., Rosa R.M., Batlle D. Hypokalemia associated with acute colonic pseudo-obstruction in an ESRD patient. Clin Nephrol. 2017;87:152–156.
    1. Weng Y.M., Chen S.Y., Chen H.C. Hypermagnesemia in a constipated female. J Emerg Med. 2013;44:e57–e60.
    1. Arnaud M.J. Mild dehydration: a risk factor of constipation? Eur J Clin Nutr. 2003;57(Suppl 2):S88–S95.
    1. Sutton D., Ovington S., Engel B. A multi-centre, randomised trial to assess whether increased dietary fibre intake (using a fibre supplement or high-fibre foods) produces healthy bowel performance and reduces laxative requirement in free living patients on peritoneal dialysis. J Ren Care. 2014;40:157–163.
    1. De Giorgio R., Ruggeri E., Stanghellini V. Chronic constipation in the elderly: a primer for the gastroenterologist. BMC Gastroenterol. 2015;15:130.
    1. Kosmadakis G., Albaret J., Da Costa Correia E. Constipation in peritoneal dialysis patients. Perit Dial Int. 2019;39:399–404.
    1. Palmer S.C., Gardner S., Tonelli M. Phosphate-binding agents in adults with CKD: a network meta-analysis of randomized trials. Am J Kidney Dis. 2016;68:691–702.
    1. Hoibian E., Florens N., Koppe L. Distal colon motor dysfunction in mice with chronic kidney disease: putative role of uremic toxins. Toxins (Basel) 2018;10(5)
    1. Ramezani A., Raj D.S. The gut microbiome, kidney disease, and targeted interventions. J Am Soc Nephrol. 2014;25:657–670.
    1. Zhao Y., Yu Y.B. Intestinal microbiota and chronic constipation. Springerplus. 2016;5:1130.
    1. Sabatino A., Regolisti G., Brusasco I. Alterations of intestinal barrier and microbiota in chronic kidney disease. Nephrol Dial Transplant. 2015;30:924–933.
    1. Khalif I.L., Quigley E.M., Konovitch E.A., Maximova I.D. Alterations in the colonic flora and intestinal permeability and evidence of immune activation in chronic constipation. Dig Liver Dis. 2005;37:838–849.
    1. Simren M., Barbara G., Flint H.J. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut. 2013;62:159–176.
    1. Parthasarathy G., Chen J., Chen X. Relationship between microbiota of the colonic mucosa vs feces and symptoms, colonic transit, and methane production in female patients with chronic constipation. Gastroenterology. 2016;150:367–379.e1.
    1. Barbara G., Stanghellini V., Brandi G. Interactions between commensal bacteria and gut sensorimotor function in health and disease. Am J Gastroenterol. 2005;100:2560–2568.
    1. Chen Y.Y., Chen D.Q., Chen L. Microbiome-metabolome reveals the contribution of gut-kidney axis on kidney disease. J Transl Med. 2019;17:5.
    1. Vaziri N.D. CKD impairs barrier function and alters microbial flora of the intestine: a major link to inflammation and uremic toxicity. Curr Opin Nephrol Hypertens. 2012;21:587–592.
    1. Vaziri N.D., Wong J., Pahl M. Chronic kidney disease alters intestinal microbial flora. Kidney Int. 2013;83:308–315.
    1. Wong J., Piceno Y.M., DeSantis T.Z. Expansion of urease- and uricase-containing, indole- and p-cresol-forming and contraction of short-chain fatty acid-producing intestinal microbiota in ESRD. Am J Nephrol. 2014;39:230–237.
    1. Sumida K., Kovesdy C.P. The gut-kidney-heart axis in chronic kidney disease. Physiol Int. 2019;106:195–206.
    1. Cupisti A., Kovesdy C.P., D'Alessandro C., Kalantar-Zadeh K. Dietary approach to recurrent or chronic hyperkalaemia in patients with decreased kidney function. Nutrients. 2018;10(3)
    1. St-Jules D.E., Goldfarb D.S., Sevick M.A. Nutrient non-equivalence: does restricting high-potassium plant foods help to prevent hyperkalemia in hemodialysis patients? J Ren Nutr. 2016;26:282–287.
    1. Hayes C.P., Jr., McLeod M.E., Robinson R.R. An extravenal mechanism for the maintenance of potassium balance in severe chronic renal failure. Trans Assoc Am Physicians. 1967;80:207–216.
    1. Martin R.S., Panese S., Virginillo M. Increased secretion of potassium in the rectum of humans with chronic renal failure. Am J Kidney Dis. 1986;8:105–110.
    1. Mathialahan T., Maclennan K.A., Sandle L.N. Enhanced large intestinal potassium permeability in end-stage renal disease. J Pathol. 2005;206:46–51.
    1. Barsotti G., Morelli E., Cupisti A. A low-nitrogen low-phosphorus vegan diet for patients with chronic renal failure. Nephron. 1996;74:390–394.
    1. Cupisti A., Morelli E., Meola M. Vegetarian diet alternated with conventional low-protein diet for patients with chronic renal failure. J Ren Nutr. 2002;12:32–37.
    1. Moorthi R.N., Armstrong C.L., Janda K. The effect of a diet containing 70% protein from plants on mineral metabolism and musculoskeletal health in chronic kidney disease. Am J Nephrol. 2014;40:582–591.
    1. Di Iorio B.R., Di Micco L., Marzocco S. Very low-protein diet (VLPD) reduces metabolic acidosis in subjects with chronic kidney disease: the “nutritional light signal” of the renal acid load. Nutrients. 2017;9(1)
    1. Sonnenberg A., Koch T.R. Physician visits in the United States for constipation: 1958 to 1986. Dig Dis Sci. 1989;34:606–611.
    1. Rantis P.C., Jr., Vernava A.M., 3rd, Daniel G.L., Longo W.E. Chronic constipation--is the work-up worth the cost? Dis Colon Rectum. 1997;40:280–286.
    1. Menees S.B., Guentner A., Chey S.W. How do us gastroenterologists use over-the-counter and prescription medications in patients with gastroesophageal reflux and chronic constipation? Am J Gastroenterol. 2015;110:1516–1525.
    1. Su C.Y., Pei J., Lu X.H. Gastrointestinal symptoms predict peritonitis rates in CAPD patients. Clin Nephrol. 2012;77:267–274.
    1. Chang S.S., Huang N., Hu H.Y. Patients with end-stage renal disease were at an increased risk of hospitalization for acute diverticulitis. Medicine (Baltimore) 2016;95:e4881.
    1. Adams-Carr K.L., Bestwick J.P., Shribman S. Constipation preceding Parkinson's disease: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2016;87:710–716.
    1. Ponnusamy K., Choi J.N., Kim J. Microbial community and metabolomic comparison of irritable bowel syndrome faeces. J Med Microbiol. 2011;60(Pt 6):817–827.
    1. Kim S.E., Choi S.C., Park K.S. Change of fecal flora and effectiveness of the short-term VSL#3 probiotic treatment in patients with functional constipation. J Neurogastroenterol Motil. 2015;21:111–120.
    1. Tap J., Derrien M., Tornblom H. Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome. Gastroenterology. 2017;152:111–123.e8.
    1. Bowman J.D., Surani S., Horseman M.A. Endotoxin, Toll-like receptor-4, and atherosclerotic heart disease. Curr Cardiol Rev. 2017;13:86–93.
    1. Tang W.H., Wang Z., Levison B.S. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med. 2013;368:1575–1584.
    1. Kop W.J., Stein P.K., Tracy R.P. Autonomic nervous system dysfunction and inflammation contribute to the increased cardiovascular mortality risk associated with depression. Psychosom Med. 2010;72:626–635.
    1. Vikenes K., Farstad M., Nordrehaug J.E. Serotonin is associated with coronary artery disease and cardiac events. Circulation. 1999;100:483–489.
    1. Costedio M.M., Coates M.D., Brooks E.M. Mucosal serotonin signaling is altered in chronic constipation but not in opiate-induced constipation. Am J Gastroenterol. 2010;105:1173–1180.
    1. Pstras L., Thomaseth K., Waniewski J. The Valsalva manoeuvre: physiology and clinical examples. Acta Physiol (Oxf) 2016;217:103–119.
    1. Ma W., Li Y., Heianza Y. Associations of bowel movement frequency with risk of cardiovascular disease and mortality among US women. Sci Rep. 2016;6:33005.
    1. Lekawanvijit S., Kompa A.R., Wang B.H. Cardiorenal syndrome: the emerging role of protein-bound uremic toxins. Circ Res. 2012;111:1470–1483.
    1. Poesen R., Meijers B., Evenepoel P. The colon: an overlooked site for therapeutics in dialysis patients. Semin Dial. 2013;26:323–332.
    1. Ramos C.I., Armani R.G., Canziani M.E. Bowel habits and the association with uremic toxins in non-dialysis-dependent chronic kidney disease patients. J Ren Nutr. 2020;30:31–35.
    1. De Schryver A.M., Samsom M., Smout A.I. Effects of a meal and bisacodyl on colonic motility in healthy volunteers and patients with slow-transit constipation. Dig Dis Sci. 2003;48:1206–1212.
    1. Muller-Lissner S.A., Kamm M.A., Scarpignato C., Wald A. Myths and misconceptions about chronic constipation. Am J Gastroenterol. 2005;100:232–242.
    1. Suares N.C., Ford A.C. Systematic review: the effects of fibre in the management of chronic idiopathic constipation. Aliment Pharmacol Ther. 2011;33:895–901.
    1. Kelly J.T., Palmer S.C., Wai S.N. Healthy dietary patterns and risk of mortality and ESRD in CKD: a meta-analysis of cohort studies. Clin J Am Soc Nephrol. 2017;12:272–279.
    1. Koppe L., Mafra D., Fouque D. Probiotics and chronic kidney disease. Kidney Int. 2015;88:958–966.
    1. Koppe L., Fouque D. Microbiota and prebiotics modulation of uremic toxin generation. Panminerva Med. 2017;59:173–187.
    1. Andresen V., Layer P. Medical therapy of constipation: current standards and beyond. Visc Med. 2018;34:123–127.
    1. Ford A.C., Moayyedi P., Lacy B.E. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol. 2014;109(Suppl 1):S2–S26. quiz S27.
    1. Mimidis K., Mourvati E., Kaliontzidou M. Efficacy of polyethylene glycol in constipated CAPD patients. Perit Dial Int. 2005;25:601–603.
    1. Xing J.H., Soffer E.E. Adverse effects of laxatives. Dis Colon Rectum. 2001;44:1201–1209.
    1. Tayebi-Khosroshahi H., Habibzadeh A., Niknafs B. The effect of lactulose supplementation on fecal microflora of patients with chronic kidney disease; a randomized clinical trial. J Renal Inj Prev. 2016;5:162–167.
    1. Tian H., Ding C., Gong J. Treatment of slow transit constipation with fecal microbiota transplantation: a pilot study. J Clin Gastroenterol. 2016;50:865–870.
    1. Tian H., Ge X., Nie Y. Fecal microbiota transplantation in patients with slow-transit constipation: a randomized, clinical trial. PLoS One. 2017;12
    1. Ford A.C., Suares N.C. Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis. Gut. 2011;60:209–218.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa